Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells
Bu Gyeom Kim, Bo Ram Kim, Dae Yeong Kim, Woo Young Kim, Sanghee Kang, Sun Il Lee, Sang Cheul Oh · 2024
Read Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells by Bu Gyeom Kim, Bo Ram Kim, Dae Yeong Kim, Woo Young Kim, Sanghee Kang, Sun Il Lee, Sang Cheul Oh (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11612622.txt.
Description
Triple-negative breast cancer lacks the usual drug targets, and one immunotherapy helps only some patients. Bu Gyeom Kim and co-authors test an unlikely ally: cannabidiol, the non-intoxicating cannabis compound. In cancer cells, the compound raised the level of PD-L1 — paradoxically, the very shield the immunotherapy attacks — by switching on an internal alarm pathway that senses stray DNA.
More of the target on the cell surface gave the antibody drug more to strike. In dish and animal experiments, the combination produced stronger anticancer immune responses than either part alone. The authors trace the chain from the compound through the alarm pathway to the raised shield, and they propose cannabidiol as a candidate partner for checkpoint immunotherapy in this hard-to-treat cancer. The work is preclinical, pointing toward combination strategies rather than a ready treatment.
Catalog record
| CREATOR | Bu Gyeom Kim, Bo Ram Kim, Dae Yeong Kim, Woo Young Kim, Sanghee Kang, Sun Il Lee, Sang Cheul Oh |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |